Use of Ependymoma Cell Lines to Test for New Therapeutic Vulnerabilities

Email Principal Investigator
Drug/CRISPR Screen
Asset 21.png

Marcel Kool

Hopp Children's Cancer Center
Heidelberg, Germany

CBTN Specimen

CBTN Pre-clinical Models

About this


Ependymoma is a disease with nine distinct forms where two of the most common and aggressive forms occur primarily in children. Research into the main drivers of each form has been successful, but there are still very few therapeutic options available to patients. Recent studies have identified vulnerabilities in the ependymoma genome that may pave the way for new therapies. Newly established ependymoma cell cultures from the CBTN will be utilized to validate these discoveries.

Ask The


Ask the scientists

What are the goals of this project?

Previous studies have identified ependymoma-specific genes that could serve as targets for gene editing. The project seeks to validate those results.

What is the impact of this project?

Validation of previous research into the genetics of ependymoma could lead to new targets for drug, gene, and immuno-therapy.

Why is the CBTN request important to this project?

The availability of samples needed for this sort of research is limited, so the cell lines provided by CBTN are of high value to this project.

Specimen Data

The Children's Brain Tumor Network will contribute to this project by providing cell lines and PDX models.